Using a Monoclonal Antibody Plus Chemotherapy in Patients With DLBCL

Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL

During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.

What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL

In the second part of a 2-article series, Matthew A. Lunning, DO, FACP, leads a discussion on how to best manage toxicities from tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

Breaking Down Considerations for Tafasitamab/Lenalidomide in DLBCL

In the first part of a 2-article series, Matthew A. Lunning, DO, FACP, takes into consideration the perspectives of his peers on the use of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

Tafasitamab/Lenalidomide in R/R DLBCL Shows Benefit with Long-Term Use

In the second article of a 2-part series, Hayder Saeed, MD, discusses the long-term use of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma and how the combination therapy compares in the real-world setting.

Updated Data Show Efficacy of Tafasitamab/Lenalidomide in R/R DLBCL

In the first article of a 2-part series, Hayder Saeed, MD, discusses the 5-year follow up data from the L-MIND study, which shows the continuing efficacy of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

Targeted Therapy With Tafasitamab Proves Effective in DLBCL

Hayder Saeed, MD, discusses how the mechanism of action of tafasitamab makes the therapy a potent cancer cell killer for patients with diffuse large B-cell lymphoma.

Physicians Respond to 5-Year Tafasitamab/Lenalidomide Data for R/R DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen J. Schuster, MD, discussed the use of tafasitamab plus lenalidomide in patients with diffuse large B-cell lymphoma including managing adverse events and treating patients after disease progression.

Long-Term Combination Data Show Most Benefit in Second-Line DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen A. Schuster, MD, discussed the 5-year outcomes of the L-MIND trial of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

Considering Alternatives to CAR T-Cell Therapy for Primary Refractory DLBCL

During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.

Tafasitamab/Lenalidomide Shows Efficacy, Tolerability for R/R DLBCL

During a live virtual event, Brian T. Hill, MD, discussed the results of the L-MIND study of tafasitamab plus lenalidomide for patients with relapsed/refractory diffuse B-cell lymphoma.